CCNT1 and familial pancreatic carcinoma: Overall, new chemical entity based on symmetrical bis-pyrrolo[2,3-d]pyrimidines connected through di(ethylene-1,2,3-triazolyl)phenyl spacer was identified as a novel CDK9/cyclin T1 inhibitor for potential treatment of pancreatic cancer.